Headlines

Novartis Paid $465M for Eyecare Company

Published

7 years ago

January 30, 2017

The deal closed Jan. 20.

Novartis paid $465 million for Encore Vision Inc., a privately held company in Fort Worth, TX, reports DallasNews.com.

The acqusition was announced in December. It closed on Jan. 20, according to a document filed with the U.S. Securities and Exchange Commission.

The price tag was not made public in the December announcement.

Encore is developing an eye drop treatment for presbyopia.

Novartis, parent company of Alcon, said in the SEC filing that the preliminary fair value of the deal was $465 million.

The amount included an initial cash payment of $375 million “before ordinary purchase price adjustments” along with $90 million that would go to shareholders. Shareholders are eligible to receive the $90 million “upon achievement of specified development and commercialization milestones.”

Read more at DallasNews.com

click to Comment(Comment)

Up Next

Lifestyle Brand Enters Eyewear Market with McGee Group

Don't Miss

Eyewear Retailer Takes Revenge on Warby Parker

The Best Overall Progressive Lens, Now Powered by AI

Engineered with Behavioral Artificial Intelligence and utilizing new XR-motion™ technology, Varilux XR series goes beyond prescription and eye physiology to consider the patient’s visual behavior and design a progressive lens that respects how
their eyes naturally move.

Varilux XR series comes in two versions, Varilux® XR design and Varilux® XR track. The Varilux XR track lens provides an additional level of personalization by incorporating the exclusive Near Vision Behavior Measurement, providing up to 25% more near vision width³ according to the patient’s need, so patients get the highest level of customization.

Discover Varilux XR series and enjoy instantly sharp vision in motion⁴ and seamless transitions from near to far.

For more information, visit here.